{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:09:38Z","timestamp":1793812178386,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40121-025-01159-6","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T16:36:14Z","timestamp":1745771774000},"page":"1183-1200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tackling CMV in Transplant Recipients: Past, Present, and Future"],"prefix":"10.1007","volume":"14","author":[{"given":"Tal","family":"Schlaeffer-Yosef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-0428","authenticated-orcid":false,"given":"Lior","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"1159_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/RMV.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et\u00a0al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29: e2034. https:\/\/doi.org\/10.1002\/RMV.2034.","journal-title":"Rev Med Virol"},{"key":"1159_CR2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, et\u00a0al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119\u201327. https:\/\/doi.org\/10.1016\/S2352-3026(15)00289-6.","journal-title":"Lancet Haematol"},{"key":"1159_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1086\/528718","volume":"46","author":"SK Arthurs","year":"2008","unstructured":"Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et\u00a0al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney. Transplantation. 2008;46:840\u20136. https:\/\/doi.org\/10.1086\/528718.","journal-title":"Transplantation"},{"key":"1159_CR4","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/BLOOD-2003-10-3616","volume":"103","author":"M Boeckh","year":"2004","unstructured":"Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003\u20138. https:\/\/doi.org\/10.1182\/BLOOD-2003-10-3616.","journal-title":"Blood"},{"key":"1159_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01944-2","author":"KA Eberhardt","year":"2023","unstructured":"Eberhardt KA, Jung V, Knops E, Heger E, Wirtz M, Steger G, et\u00a0al. CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. Bone Marrow Transplant. 2023. https:\/\/doi.org\/10.1038\/s41409-023-01944-2.","journal-title":"Bone Marrow Transplant"},{"key":"1159_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/CTR.13512","author":"RR Razonable","year":"2019","unstructured":"Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients\u2014guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019. https:\/\/doi.org\/10.1111\/CTR.13512.","journal-title":"Clin Transplant"},{"key":"1159_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","volume":"71","author":"L Sergio Azevedo","year":"2015","unstructured":"Sergio Azevedo L, Camera Pierrotti L, Abdala E, FigueiredoCosta S, Strabelli TMV, Vidal Campos S, et\u00a0al. Cytomegalovirus infection in transplant recipients. Clinics. 2015;71:515\u201323. https:\/\/doi.org\/10.6061\/clinics\/2015(07)09.","journal-title":"Clinics"},{"key":"1159_CR8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1172\/JCI45449","volume":"121","author":"M Boeckh","year":"2011","unstructured":"Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Investig. 2011;121:1673\u201380. https:\/\/doi.org\/10.1172\/JCI45449.","journal-title":"J Clin Investig"},{"key":"1159_CR9","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/01.TP.0000230460.42558.B0","volume":"82","author":"A Hartmann","year":"2006","unstructured":"Hartmann A, Sagedal S, Hjelmes\u00e6th J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82:S15\u20137. https:\/\/doi.org\/10.1097\/01.TP.0000230460.42558.B0.","journal-title":"Transplantation"},{"key":"1159_CR10","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJM199112053252303\/ASSET\/B189B42A-6F5C-49E2-B358-8A8E143911DE\/ASSETS\/IMAGES\/LARGE\/NEJM199112053252303_F5.JPG","volume":"325","author":"JM Goodrich","year":"1991","unstructured":"Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et\u00a0al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601\u20137. https:\/\/doi.org\/10.1056\/NEJM199112053252303\/ASSET\/B189B42A-6F5C-49E2-B358-8A8E143911DE\/ASSETS\/IMAGES\/LARGE\/NEJM199112053252303_F5.JPG.","journal-title":"N Engl J Med"},{"key":"1159_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003\/ASSET\/IMAGES\/3TT3.JPG","volume":"118","author":"JM Goodrich","year":"1993","unstructured":"Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173\u20138. https:\/\/doi.org\/10.7326\/0003-4819-118-3-199302010-00003\/ASSET\/IMAGES\/3TT3.JPG.","journal-title":"Ann Intern Med"},{"key":"1159_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/CID\/CIAE321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, et\u00a0al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024;79:787\u201394. https:\/\/doi.org\/10.1093\/CID\/CIAE321.","journal-title":"Clin Infect Dis"},{"key":"1159_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ajt.12006","volume":"13","author":"CN Kotton","year":"2013","unstructured":"Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13:24\u201340. https:\/\/doi.org\/10.1111\/ajt.12006.","journal-title":"Am J Transplant"},{"key":"1159_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/clinids\/12.Supplement_7.S727","volume":"12","author":"S Chou","year":"1990","unstructured":"Chou S. Newer methods for diagnosis of cytomegalovirus infection. Clin Infect Dis. 1990;12:727\u201336.","journal-title":"Clin Infect Dis"},{"key":"1159_CR15","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, et\u00a0al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260\u201372. https:\/\/doi.org\/10.1016\/S1473-3099(19)30107-0.","journal-title":"Lancet Infect Dis"},{"issue":"13","key":"1159_CR16","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.3390\/DIAGNOSTICS13213310","volume":"2023","author":"X Li","year":"2023","unstructured":"Li X, Zhong Y, Qiao Y, Li H, Hu X, Imani S, et\u00a0al. Advances and challenges in cytomegalovirus detection methods for liver transplant donors. Diagnostics. 2023;2023(13):3310. https:\/\/doi.org\/10.3390\/DIAGNOSTICS13213310.","journal-title":"Diagnostics"},{"key":"1159_CR17","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1128\/JCM.41.7.3167-3174.2003\/ASSET\/64E5AED5-FCAB-4ABF-AF79-46145CEA532D\/ASSETS\/GRAPHIC\/JM0731679004.JPEG","volume":"41","author":"XL Pang","year":"2003","unstructured":"Pang XL, Chui L, Fenton J, LeBlanc B, Preiksaitis JK. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol. 2003;41:3167\u201374. https:\/\/doi.org\/10.1128\/JCM.41.7.3167-3174.2003\/ASSET\/64E5AED5-FCAB-4ABF-AF79-46145CEA532D\/ASSETS\/GRAPHIC\/JM0731679004.JPEG.","journal-title":"J Clin Microbiol"},{"key":"1159_CR18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1128\/CMR.00015-13","volume":"26","author":"RR Razonable","year":"2013","unstructured":"Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 2013;26:703\u201327. https:\/\/doi.org\/10.1128\/CMR.00015-13.","journal-title":"Clin Microbiol Rev"},{"key":"1159_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","volume":"342","author":"EJ Ariza-Heredia","year":"2014","unstructured":"Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342:1\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2013.09.004.","journal-title":"Cancer Lett"},{"key":"1159_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et\u00a0al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102:900\u201331. https:\/\/doi.org\/10.1097\/TP.0000000000002191.","journal-title":"Transplantation"},{"key":"1159_CR21","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1093\/JPIDS\/PIAD059","volume":"13","author":"KGV Deray","year":"2024","unstructured":"Deray KGV, Danziger-Isakov LA, Downes KJ. Current and emerging antiviral agents in the prevention and treatment of cytomegalovirus in pediatric transplant recipients. J Pediatric Infect Dis Soc. 2024;13:S14-21. https:\/\/doi.org\/10.1093\/JPIDS\/PIAD059.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"1159_CR22","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1001\/JAMA.1987.03390220080025","volume":"257","author":"A Erice","year":"1987","unstructured":"Erice A, Jordan MC, Chace BA, Fletcher C, Chinnock BJ, Balfour HH. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 1987;257:3082\u20137. https:\/\/doi.org\/10.1001\/JAMA.1987.03390220080025.","journal-title":"JAMA"},{"key":"1159_CR23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/CID\/CIW370","volume":"63","author":"JK Preiksaitis","year":"2016","unstructured":"Preiksaitis JK, Hayden RT, Tong Y, Pang XL, Fryer JF, Heath AB, et\u00a0al. Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples. Clin Infect Dis. 2016;63:583\u20139. https:\/\/doi.org\/10.1093\/CID\/CIW370.","journal-title":"Clin Infect Dis"},{"key":"1159_CR24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/INFDIS\/JIY592","volume":"219","author":"L El Haddad","year":"2019","unstructured":"El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, et\u00a0al. The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients. J Infect Dis. 2019;219:898\u2013907. https:\/\/doi.org\/10.1093\/INFDIS\/JIY592.","journal-title":"J Infect Dis"},{"key":"1159_CR25","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","volume":"92","author":"CS Crumpacker","year":"1992","unstructured":"Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992;92:3S-7S.","journal-title":"Am J Med"},{"key":"1159_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41409-018-0200-y","volume":"53","author":"E Metafuni","year":"2018","unstructured":"Metafuni E, Chiusolo P, Sica S, Laurenti L, Bregante S, Teresa M, et\u00a0al. Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. Bone Marrow Transplant. 2018;53:1560\u20137. https:\/\/doi.org\/10.1038\/s41409-018-0200-y.","journal-title":"Bone Marrow Transplant"},{"key":"1159_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/idr16010005","volume":"16","author":"J Piret","year":"2024","unstructured":"Piret J, Boivin G. Management of cytomegalovirus infections in the era of the novel antiviral players, letermovir and maribavir. Infect Dis Rep. 2024;16:65\u201382. https:\/\/doi.org\/10.3390\/idr16010005.","journal-title":"Infect Dis Rep"},{"key":"1159_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/nejmoa1303688","volume":"369","author":"FM Marty","year":"2013","unstructured":"Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, et\u00a0al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227\u201336. https:\/\/doi.org\/10.1056\/nejmoa1303688.","journal-title":"N Engl J Med"},{"key":"1159_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","volume":"25","author":"FM Marty","year":"2019","unstructured":"Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et\u00a0al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25:369\u201381. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.038.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1159_CR30","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/nejmoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et\u00a0al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344. https:\/\/doi.org\/10.1056\/nejmoa1706640.","journal-title":"N Engl J Med"},{"key":"1159_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2023.9106","volume":"330","author":"AP Limaye","year":"2023","unstructured":"Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, et\u00a0al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330:33\u201342. https:\/\/doi.org\/10.1001\/jama.2023.9106.","journal-title":"JAMA"},{"key":"1159_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, et\u00a0al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75:690\u2013701. https:\/\/doi.org\/10.1093\/cid\/ciab988.","journal-title":"Clin Infect Dis"},{"key":"1159_CR33","unstructured":"ECIL 10. Resources. n.d. https:\/\/www.ecil-leukaemia.com\/en\/resources\/resources-ecil. Accessed 3 Mar 2025."},{"key":"1159_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/CTR.15300","volume":"38","author":"J Cui","year":"2024","unstructured":"Cui J, Zhou Y, Zhao K, Li X, Zhang H, Zhang X, et\u00a0al. Application of CMV-IVIg as prophylaxis against cytomegalovirus reactivation in allogeneic hematopoietic stem cell transplantation patients. Clin Transplant. 2024;38: e15300. https:\/\/doi.org\/10.1111\/CTR.15300.","journal-title":"Clin Transplant"},{"key":"1159_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/PBC.26420","volume":"64","author":"G Goldstein","year":"2017","unstructured":"Goldstein G, Rutenberg TF, Mendelovich SL, Hutt D, Oikawa MT, Toren A, et\u00a0al. The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients. Pediatr Blood Cancer. 2017;64: e26420. https:\/\/doi.org\/10.1002\/PBC.26420.","journal-title":"Pediatr Blood Cancer"},{"key":"1159_CR36","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2019.048","author":"M Malagola","year":"2019","unstructured":"Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, et\u00a0al. CMV management with specific immunoglobulins: a multicentric retrospective analysis on 92 allotransplanted patients. Mediterr J Hematol Infect Dis. 2019. https:\/\/doi.org\/10.4084\/MJHID.2019.048.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1159_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","volume":"27","author":"P Raanani","year":"2009","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27:770\u201381. https:\/\/doi.org\/10.1200\/JCO.2008.16.8450.","journal-title":"J Clin Oncol"},{"key":"1159_CR38","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1002\/JMV.26861","volume":"93","author":"A Gilioli","year":"2021","unstructured":"Gilioli A, Messerotti A, Bresciani P, Cuoghi A, Pioli V, Colasante C, et\u00a0al. Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV-IG prophylaxis: a monocentric retrospective analysis. J Med Virol. 2021;93:6292\u2013300. https:\/\/doi.org\/10.1002\/JMV.26861.","journal-title":"J Med Virol"},{"key":"1159_CR39","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","volume":"333","author":"EA Walter","year":"1995","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et\u00a0al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038\u201344. https:\/\/doi.org\/10.1056\/NEJM199510193331603.","journal-title":"N Engl J Med"},{"key":"1159_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-007735","volume":"12","author":"C Ma","year":"2024","unstructured":"Ma C, Chen P, Du J, Wang L, Lu N, Sun J, et\u00a0al. Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation. J Immunother Cancer. 2024;12: e007735. https:\/\/doi.org\/10.1136\/JITC-2023-007735.","journal-title":"J Immunother Cancer"},{"key":"1159_CR41","doi-asserted-by":"publisher","first-page":"3240330","DOI":"10.1158\/1078-0432.CCR-22-2415","volume":"29","author":"T Pfeiffer","year":"2023","unstructured":"Pfeiffer T, Tzannou I, Wu M, Ramos C, Sasa G, Martinez C, et\u00a0al. Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin Cancer Res. 2023;29:3240330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2415.","journal-title":"Clin Cancer Res"},{"key":"1159_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/RMV.2017","volume":"29","author":"D Navarro","year":"2019","unstructured":"Navarro D, Fern\u00e1ndez-Ruiz M, Aguado JM, Sandon\u00eds V, P\u00e9rez-Romero P. Going beyond serology for stratifying the risk of CMV infection in transplant recipients. Rev Med Virol. 2019;29: e2017. https:\/\/doi.org\/10.1002\/RMV.2017.","journal-title":"Rev Med Virol"},{"key":"1159_CR43","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.039","volume":"16","author":"F Herrera","year":"2024","unstructured":"Herrera F, Torres D, Querci M, Rearte AN, Temporiti E, Riera L, et\u00a0al. Letermovir primary cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients: real-life data from a university hospital in Argentina. Mediterr J Hematol Infect Dis. 2024;16: e2024039. https:\/\/doi.org\/10.4084\/MJHID.2024.039.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1159_CR44","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/J.BBMT.2020.01.015","volume":"26","author":"D Huntley","year":"2020","unstructured":"Huntley D, Talaya A, Gim\u00e9nez E, Mart\u00ednez A, Hern\u00e1ndez-Boluda JC, Hernani R, et\u00a0al. Features of cytomegalovirus DNAemia blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transplant. 2020;26:972\u20137. https:\/\/doi.org\/10.1016\/J.BBMT.2020.01.015.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1159_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/J.CMI.2024.03.001","volume":"30","author":"A Febres-Aldana","year":"2024","unstructured":"Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle TL, Rondon G, Sassine J, et\u00a0al. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience. Clin Microbiol Infect. 2024;30:803\u20139. https:\/\/doi.org\/10.1016\/J.CMI.2024.03.001.","journal-title":"Clin Microbiol Infect"},{"key":"1159_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/TID.14183","author":"CN Kotton","year":"2023","unstructured":"Kotton CN, Torre-Cisneros J, Yakoub-Agha I, Alain S, Al-Maghrabi R, Beauvais D, et\u00a0al. Slaying the \u201ctroll of transplantation\u201d-New frontiers in cytomegalovirus management: a report from the CMV International Symposium 2023. Transpl Infect Dis. 2023. https:\/\/doi.org\/10.1111\/TID.14183.","journal-title":"Transpl Infect Dis"},{"key":"1159_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/BLOOD.2020009396","volume":"138","author":"D Zamora","year":"2021","unstructured":"Zamora D, Duke ER, Xie H, Edmison BC, Akoto B, Kiener R, et\u00a0al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138:34\u201343. https:\/\/doi.org\/10.1182\/BLOOD.2020009396.","journal-title":"Blood"},{"key":"1159_CR48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/sj.bmt.1705507","volume":"38","author":"G Avetisyan","year":"2006","unstructured":"Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:687\u201392. https:\/\/doi.org\/10.1038\/sj.bmt.1705507.","journal-title":"Bone Marrow Transplant"},{"key":"1159_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/fvl.12.8","volume":"7","author":"RC La","year":"2012","unstructured":"La RC, Diamond DJ. The immune response to human CMV. Future Virol. 2012;7:279\u201393. https:\/\/doi.org\/10.2217\/fvl.12.8.","journal-title":"Future Virol"},{"key":"1159_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw064","author":"L Nesher","year":"2016","unstructured":"Nesher L, Shah DP, Ariza-Heredia EJ, Azzi JM, Siddiqui HK, Ghantoji SS, et\u00a0al. Utility of the enzyme-linked immunospot interferon-\u03b3-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J Infect Dis. 2016. https:\/\/doi.org\/10.1093\/infdis\/jiw064.","journal-title":"J Infect Dis"},{"key":"1159_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189488","author":"H Lee","year":"2017","unstructured":"Lee H, Park KH, Ryu JH, Choi A-R, Yu JH, Lim J, et\u00a0al. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients. PLoS ONE. 2017. https:\/\/doi.org\/10.1371\/journal.pone.0189488.","journal-title":"PLoS ONE"},{"key":"1159_CR52","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1128\/JCM.00563-13","volume":"51","author":"D Abate","year":"2013","unstructured":"Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, et\u00a0al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol. 2013;51:2501\u20137. https:\/\/doi.org\/10.1128\/JCM.00563-13.","journal-title":"J Clin Microbiol"},{"key":"1159_CR53","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/J.1600-6143.2009.02618.X","volume":"9","author":"D Kumar","year":"2009","unstructured":"Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et\u00a0al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009;9:1214\u201322. https:\/\/doi.org\/10.1111\/J.1600-6143.2009.02618.X.","journal-title":"Am J Transplant"},{"key":"1159_CR54","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1093\/CID\/CIZ1210","volume":"71","author":"RF Chemaly","year":"2020","unstructured":"Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, et\u00a0al. Cytomegalovirus (CMV) cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin Infect Dis. 2020;71:2365\u201374. https:\/\/doi.org\/10.1093\/CID\/CIZ1210.","journal-title":"Clin Infect Dis"},{"key":"1159_CR55","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/CID\/CIAD575","volume":"78","author":"O Manuel","year":"2024","unstructured":"Manuel O, Laager M, Hirzel C, Neofytos D, Walti LN, Hoenger G, et\u00a0al. Immune monitoring-guided versus fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients: a multicenter, randomized clinical trial. Clin Infect Dis. 2024;78:312\u201323. https:\/\/doi.org\/10.1093\/CID\/CIAD575.","journal-title":"Clin Infect Dis"},{"key":"1159_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis818","author":"A Egli","year":"2012","unstructured":"Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis. 2012. https:\/\/doi.org\/10.1093\/cid\/cis818.","journal-title":"Clin Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01159-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01159-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01159-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:43:45Z","timestamp":1749602625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01159-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01159-6","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tal Schlaeffer-Yosef has nothing to declare. Lior Nesher has given educational lectures at conferences and has participated in advisory boards paid for by Takeda, Merck, Pfizer, and Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}